Your browser is no longer supported. Please, upgrade your browser.
Settings
CLVS Clovis Oncology, Inc. daily Stock Chart
CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-2.97 Insider Own0.50% Shs Outstand52.67M Perf Week0.67%
Market Cap1.34B Forward P/E- EPS next Y-6.21 Insider Trans-2.36% Shs Float51.14M Perf Month12.19%
Income-158.40M PEG- EPS next Q-1.73 Inst Own- Short Float23.97% Perf Quarter67.04%
Sales82.10M P/S16.35 EPS this Y56.90% Inst Trans0.84% Short Ratio4.81 Perf Half Y-26.92%
Book/sh4.44 P/B5.74 EPS next Y9.60% ROA-39.20% Target Price29.18 Perf Year-52.87%
Cash/sh11.48 P/C2.22 EPS next 5Y29.40% ROE-105.10% 52W Range11.50 - 65.24 Perf YTD41.93%
Dividend- P/FCF- EPS past 5Y-5.70% ROI-27.30% 52W High-60.93% Beta2.05
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin79.80% 52W Low121.65% ATR1.22
Employees360 Current Ratio9.00 Sales Q/Q35.70% Oper. Margin- RSI (14)60.20 Volatility3.70% 4.95%
OptionableYes Debt/Eq2.46 EPS Q/Q-37.60% Profit Margin- Rel Volume0.77 Prev Close25.47
ShortableYes LT Debt/Eq2.46 EarningsFeb 26 BMO Payout- Avg Volume2.55M Price25.49
Recom2.00 SMA203.36% SMA5015.60% SMA200-21.23% Volume1,959,557 Change0.08%
Feb-13-19Initiated H.C. Wainwright Buy $40
Dec-04-18Upgrade Leerink Partners Mkt Perform → Outperform
Oct-31-18Downgrade JP Morgan Overweight → Neutral
Oct-19-18Resumed Piper Jaffray Neutral
Sep-25-18Initiated Leerink Partners Mkt Perform
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
Jul-07-17Initiated Gabelli & Co Buy $125
Jun-23-17Initiated Oppenheimer Perform
Jun-20-17Upgrade Janney Neutral → Buy
Jun-19-17Upgrade Chardan Capital Markets Sell → Neutral $36 → $50
Jun-16-17Resumed Credit Suisse Outperform
Jun-13-17Initiated Leerink Partners Outperform $85
May-17-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Downgrade Chardan Capital Markets Neutral → Sell $36
Jan-27-17Initiated BofA/Merrill Buy $74
Jan-26-17Upgrade Piper Jaffray Neutral → Overweight
Feb-13-19 07:30AM  New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-12-19 08:00AM  Clovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26 Business Wire
Jan-28-19 07:02AM  Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe Zacks
Jan-24-19 01:00PM  What's Behind the Biotech ETF Rally to Start 2019? Zacks
12:28PM  Clovis Oncology Announces European Commission Authorization of Rubraca® (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer Business Wire
Jan-18-19 06:41AM  Immunomedics Gets CRL From FDA for Breast Cancer Candidate Zacks +7.29%
Jan-17-19 03:50PM  Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table Investor's Business Daily
Jan-12-19 12:00PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-11-19 08:48AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
Jan-10-19 06:00AM  Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause ACCESSWIRE
Jan-08-19 12:12PM  History Says Pump the Brakes on a Clovis Oncology Stock Rally Schaeffer's Investment Research +9.99%
Jan-07-19 12:37PM  Here's Why Clovis Oncology Rose as Much as 21.9% Today Motley Fool +18.48%
08:00AM  Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018 Business Wire
Jan-02-19 04:05PM  Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire +7.96%
Dec-27-18 06:06PM  Immunomedics Enters Into Supply Deal for Breast Cancer Drug Zacks -5.07%
Dec-26-18 07:25AM  Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences What Drives Growth in Today's Competitive Landscape GlobeNewswire +9.47%
Dec-20-18 05:34PM  AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting Zacks
Dec-17-18 01:14PM  Activist Pushing Cancer Drugmaker Clovis to Pursue Sale Bloomberg -9.06%
Dec-16-18 03:07AM  Argentiere Capitals Returns, AUM and Holdings Insider Monkey
Dec-15-18 08:03AM  3 Biotechs Gilead Sciences Could Buy in March Motley Fool
Dec-14-18 08:33AM  Do Options Traders Know Something About Clovis (CLVS) Stock We Don't? Zacks
Dec-13-18 12:46PM  CHMP Grants Positive Opinion for New Indication of Clovis Oncologys Rubraca® (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer Business Wire
Dec-11-18 12:42PM  Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate Benzinga
Dec-10-18 11:00AM  Biotech Stocks Beating the Market ACCESSWIRE
08:45AM  Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher Zacks
Dec-09-18 01:27AM  Should You Avoid Clovis Oncology Inc (CLVS)? Insider Monkey
Dec-08-18 05:36PM  Could These Be the Next 2 Biotech Buyouts? Motley Fool
Dec-04-18 05:05PM  TopGainers: AutoZone, Clovis, Restoration Hardware Sidestep Selloff Investing.com
08:27AM  Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8% Zacks
08:06AM  TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer Zacks
07:37AM  Clovis Oncology Announces Positive Outcome in European Opposition Proceeding Related to Rubraca® Business Wire
06:50AM  Today's Research Reports on Trending Tickers: Clovis Oncology and Tesaro ACCESSWIRE
Dec-03-18 01:00PM  Why GlaxoSmithKline, Clovis Oncology, and Tesaro Are on the Move Today Motley Fool +10.87%
Nov-21-18 09:02AM  Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up Zacks
08:58AM  TESARO Shares Rally on Rumors of Potential Acquisition Offer Zacks
Nov-20-18 08:07AM  Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035 Business Wire +5.34%
Nov-16-18 03:32PM  9 Colorado companies make Deloittes list of fastest-growing tech companies American City Business Journals +8.48%
Nov-14-18 10:28AM  Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA Zacks
Nov-13-18 01:41PM  AstraZeneca's Lynparza Gets Priority Review in 1st Line Use Zacks +5.39%
Nov-12-18 07:40AM  Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -7.48%
07:20AM  Clovis Oncology is Testing Rubraca(R) For Multiple Oncology Indications, Analysts Review and Target ACCESSWIRE
Nov-07-18 08:00AM  Clovis Oncology to Present at the Credit Suisse 27th Annual Healthcare Conference Business Wire
Nov-06-18 02:23PM  How Clovis Oncology Inc (CLVS) Stacks Up Against Its Market Cap Peers Insider Monkey +7.34%
09:30AM  Big Biotech May Be After These Technologies ACCESSWIRE
Nov-05-18 11:25PM  Edited Transcript of CLVS earnings conference call or presentation 30-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
11:01AM  Here's Why Clovis Oncology Stock Dropped a Whopping 60.4% in October Motley Fool
Nov-01-18 07:50AM  Todays Research Reports on Stocks to Watch: Strongbridge Biopharma and Clovis Oncology ACCESSWIRE +18.06%
Oct-31-18 12:59PM  Here's Why Clovis Oncology Got Crushed Today Motley Fool -29.98%
12:50PM  Dow Gains 290 Points, but the Worst Might Not Be Over Just Because October Is Barrons.com
10:52AM  Clovis (CLVS) Q3 Earnings & Sales Lag, Rubraca Disappoints Zacks
Oct-30-18 05:45PM  Clovis Oncology (CLVS) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:36PM  Clovis Oncology stock plunges on company's wider quarterly loss, sales miss MarketWatch
04:42PM  Clovis: 3Q Earnings Snapshot Associated Press
04:05PM  Clovis Oncology Announces Third Quarter 2018 Operating Results Business Wire
Oct-29-18 04:14PM  Wall Street volatility erases trillions in company value, from Silicon Valley to Denver American City Business Journals -7.12%
Oct-22-18 04:26PM  These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests Investor's Business Daily -19.88%
01:06PM  Here's Why Clovis Oncology Dropped as Much as 21.2% Today Motley Fool
Oct-19-18 04:22PM  Here's Why Clovis Oncology Inc. Is Losing Ground Today Motley Fool -12.02%
02:21PM  UPDATE: Clovis stock rises 8% on promising results in prostate cancer trial MarketWatch
06:06AM  Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer at ESMO 2018 Benzinga
06:01AM  Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer (mCRPC) at ESMO 2018 Congress Business Wire
Oct-18-18 09:00AM  Analysis: Positioning to Benefit within Clovis Oncology, Destination Maternity, MSG Networks, Lindblad Expeditions, NetScout, and ANI Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Oct-17-18 03:12PM  How Clovis Calls Prices Increased Overnight TheStreet.com
Oct-16-18 08:00AM  Clovis Oncology to Announce Third Quarter 2018 Financial Results and Host Webcast Conference Call on October 30 Business Wire +9.66%
Oct-15-18 10:30AM  Cancer Companies to Watch ACCESSWIRE
Oct-11-18 04:05PM  Clovis Oncology Appoints Two New Directors to its Board Business Wire
Oct-05-18 10:55AM  Major Action in Biotech and This is The Next Winner ACCESSWIRE
Oct-03-18 11:37AM  Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC Zacks
10:03AM  Company News For Oct 3, 2018 Zacks
10:00AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
08:00AM  Today's Research Reports on Trending Tickers: Flex Pharma and Clovis Oncology ACCESSWIRE
Oct-02-18 11:27AM  Clovis Oncology stock rises 10% after 'breakthrough' designation from FDA MarketWatch +7.72%
08:00AM  Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca® (rucaparib) for Treatment of BRCA1/2-Mutated Metastatic Castration Resistant Prostate Cancer (mCRPC) Business Wire
Sep-19-18 12:36PM  Biopharmaceutical company fined for misleading investors Associated Press
09:15AM  Boulder biopharma firm, CEO and former exec settle with SEC for $20.8 million American City Business Journals
Sep-18-18 02:09PM  SEC fines Clovis Oncology Inc., executives $20.8 million for lying about cancer drug effectiveness MarketWatch
02:07PM  Clovis Oncology, execs to pay $20 million to settle SEC charges Reuters
Sep-06-18 08:00AM  Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference Business Wire
Sep-05-18 04:17PM  This Biotech Got A Bullish Pop On Its Experimental Cancer Regimen Investor's Business Daily
Aug-31-18 09:34AM  Why Is Clovis (CLVS) Down 12.9% Since Last Earnings Report? Zacks
Aug-27-18 07:45AM  Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-08-18 08:00AM  Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial Business Wire
Aug-03-18 04:09PM  Tesaro CEO Says Its Drug 'Will Get There' Analysts Strongly Disagree Investor's Business Daily -8.34%
01:30PM  Edited Transcript of CLVS earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
11:20AM  Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-02-18 12:00PM  Boulder biotech wants to settle with the SEC for $20 million American City Business Journals -10.65%
Aug-01-18 07:10PM  Clovis Oncology (CLVS) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:05PM  Clovis: 2Q Earnings Snapshot Associated Press
04:05PM  Clovis Oncology Announces Second Quarter 2018 Operating Results Business Wire
Jul-27-18 08:20AM  Today's Research Reports on Trending Tickers: Amgen and Clovis Oncology ACCESSWIRE
Jul-25-18 01:31PM  Buy These 3 Risky Biotech Stocks TheStreet.com
Jul-18-18 08:00AM  Clovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1 Business Wire
Jul-06-18 09:23AM  Clovis Gets EU Acceptance for Rubraca Label Expansion Filing Zacks +6.41%
08:56AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
07:20AM  Free Technical Research on Clovis Oncology and Three More Biotech Equities ACCESSWIRE
Jul-05-18 08:00AM  Clovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca® (rucaparib) as Maintenance Treatment for Women with Recurrent Ovarian Cancer Business Wire
Jul-04-18 08:00AM  Today's Research Reports on Trending Tickers: Clovis Oncology and Global Blood Therapeutics ACCESSWIRE
Jun-26-18 07:50AM  Analysis: Positioning to Benefit within PBF Energy, Callaway Golf, Total System Services, Comcast, The Cheesecake Factory, and Clovis Oncology Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-21-18 08:25AM  Today's Research Reports on Trending Tickers: Clovis Oncology and Cronos Group ACCESSWIRE
Jun-14-18 08:10AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology ACCESSWIRE
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company's product candidates include lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors; and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; collaboration and license agreement with Les Laboratoires Servier; a clinical collaboration with Bristol-Myers Squibb Company; a partnership with Foundation Medicine, Inc; and a diagnostic collaboration with Myriad Genetics, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPICKSCHEN THORLEFDirectorJan 03Option Exercise0.8832,75828,74040,376Jan 03 04:45 PM
Rolfe LindseySee RemarksDec 20Sale17.721,72830,62015,872Dec 26 09:00 AM
IVERS-READ GILLIAN CSee RemarksDec 20Sale17.7282914,690187,198Dec 26 09:00 AM
Rolfe LindseySee RemarksDec 04Sale21.232846,02914,162Dec 06 05:05 PM
MUEHL DANIEL WSee RemarksDec 04Sale21.231883,9915,664Dec 06 04:45 PM
IVERS-READ GILLIAN CSee RemarksDec 04Sale21.232505,308186,152Dec 06 04:45 PM
Hooks Corwin DaleSee RemarksJun 15Sale45.4793942,6961,595Dec 27 04:55 PM
SPICKSCHEN THORLEFDirectorApr 09Sale60.024,500270,0907,618Apr 09 06:28 PM
SPICKSCHEN THORLEFDirectorMar 08Sale61.474,500276,61512,118Mar 09 08:34 PM
SPICKSCHEN THORLEFDirectorFeb 22Sale60.004,500270,00016,618Feb 23 05:14 PM